Results 121 to 130 of about 43,190 (248)

2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management

Internal Medicine Journal, EarlyView.
Abstract Direct oral anticoagulants (DOACs) are widely prescribed to prevent and treat venous and arterial thromboembolism, supported by published evidence, and are preferred over warfarin in many guidelines. Although the risk of major bleeding, in particular intracranial haemorrhage (ICH), is decreased with DOACs, gastrointestinal bleeding is ...
Huyen A. Tran, Eileen Merriman, Ross Baker, Jennifer Curnow, Laura Young, Chee Wee Tan, Simon McRae, Sanjeev D. Chunilal   +7 more
wiley   +1 more source

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [PDF]

, 2007
Grigoris Gerotziafas, Ismaı̈l Elalamy, François Depasse, Elisabeth Perzborn, M Samama   +4 more
openalex   +1 more source

The Atrial Fibrillation Registry (The FLOW‐AF Registry): Insights From the United Arab Emirates—Patient Characteristics, Treatment, and One‐Year Outcomes

Journal of Cardiovascular Electrophysiology, Volume 36, Issue 4, Page 813-823, April 2025.
ABSTRACT Background The epidemiological landscape and treatment efficacy of atrial fibrillation (AF) in the Middle East, notably in the United Arab Emirates (UAE), remain under‐explored, presenting a distinct demographic and clinical pattern compared to Western populations.
Moutaz El Kadri, Khalid AlMuti, Amrish Agrawal, Nooshin Bazargani, Mohamed Fathy Soliman Gamaleldin, Haytham Mohamed Ahmed, Omneya Hassanain, Natasha Khalife, Ghazi Radaideh, Mohamed Magdy, Wael A. Almahmeed   +10 more
wiley   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj  

Rapid Determination of Rivaroxaban by Using Terahertz Metamaterial Biosensor

Photonics
Rivaroxaban, a direct oral anticoagulant, is widely used in the management and prevention of thrombotic conditions. Dose adjustments are necessary to optimize efficacy based on individual physiological differences. However, current analytical methods are
Xinghao Huang, Jing Wu, Xu Wu, Yan Peng
doaj   +1 more source

Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) Study [PDF]

, 2008
G. Agnelli, A. Gallus, S.Z. Goldhaber
openalex   +1 more source

Vonoprazan or Proton Pump Inhibitor for Gastric Endoscopic Submucosal Dissection in Patients Taking Antithrombotic Agents

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Delayed bleeding is a major concern after gastric endoscopic submucosal dissection (ESD), especially in patients taking antithrombotic agents. The aim of this study was to evaluate the superiority of vonoprazan (VPZ) over proton pump inhibitor (PPI) in preventing delayed bleeding after gastric ESD in patients taking ...
Hiroyuki Shibata, Toshihisa Fujiyoshi, Noboru Kawata, Tomohiko Obayashi, Masaya Esaki, Masakazu Kikuchi, Naohiro Yoshida, Tsuguo Kamioka, Yoji Sasaki, Makoto Kobayashi, Muneyori Okita, Shigeyuki Matsui, Kazuhiro Furukawa, Masanao Nakamura, Naomi Kakushima, Mitsuhiro Fujishiro, Hiroki Kawashima   +16 more
wiley   +1 more source

Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery

Orthopaedic Surgery, 2019
Objective To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS).
Qiang Huang, Shu‐xing Xing, Yi Zeng, Hai‐bo Si, Zong‐ke Zhou, Bin Shen   +5 more
doaj   +1 more source

A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

BMC Health Services Research, 2012
Background Patients undergoing major orthopaedic surgery (MOS), such as total hip (THR) or total knee replacement (TKR), are at high risk of developing venous thromboembolism (VTE).
Zindel Sonja, Stock Stephanie, Müller Dirk, Stollenwerk Björn   +3 more
doaj   +1 more source

Non‐Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer

Oral Diseases, EarlyView.
ABSTRACT Background Oral squamous cell carcinoma (OSCC) represents a significant global oral health concern. Non‐anticoagulant heparin (NH) emerges as a promising solution considering the enhanced survival observed with anticoagulants in cancer treatment. Methods We used the MTS assay (0/24/48/72 h), scratch assay (MuviCyte, 0–18 h), invasion Matrigel (
S. A. Hamza, R. Paolini, N. M. O'Brien‐Simpson, W. Singleton, R. Patini, M. McCullough, A. Celentano   +6 more
wiley   +1 more source